Amino-Acid Solution

OTHER2 trials

Sponsors

ITM Solucin GmbH

Conditions

Neuroendocrine Tumors

Phase 3

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Active, not recruitingNCT03049189

ITM Solucin GmbHNeuroendocrine Tumors

Start: 2017-02-02End: 2029-11-01Updated: 2026-08-07

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Active, not recruitingNCT04919226

ITM Solucin GmbHNeuroendocrine Tumors

Start: 2021-12-21End: 2027-09-30Updated: 2025-09-10

Related Papers

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

2026-07-02

Quality of life in patients with gastroenteropancreatic neuroendocrine tumors receiving <sup>177</sup> Lu-edotreotide or everolimus: Results from the COMPETE study.

Journal of Clinical Oncology2026-05-27

Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

European Journal of Nuclear Medicine and Molecular Imaging2023-03-0650 citations

Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.

Journal of Clinical Oncology2023-02-011 citations

Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.

2022-04-136 citations

Pivotal phase III COMPOSE trial will compare <sup>177</sup>Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.

Journal of Clinical Oncology2022-01-1924 citations

Abstract CT254: COMPETE Phase III Trial - Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide vs. Everolimus in Progressive GEP-NET

Cancer Research2021-07-015 citations

COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET

Annals of Oncology2018-10-0125 citations